Literature DB >> 1738330

Augmentin-induced jaundice with a fatal outcome.

G S Hebbard1, K G Smith, P R Gibson, P S Bhathal.   

Abstract

OBJECTIVE: To report a case of death due to Augmentin-induced cholestatic hepatitis and discuss a possible drug interaction between Augmentin and oestrogenic steroids. CLINICAL FEATURES, INTERVENTION AND OUTCOME: An 81-year-old man, on oestrogen therapy for prostatic malignancy, presented with obstructive jaundice one week after completing a four-week course of Augmentin for recurrent urinary tract infection. Liver biopsy showed features of a drug-induced cholestatic hepatitis with bile duct injury. His clinical course was marked by progressive deterioration with increasing jaundice and the development of hepatic encephalopathy. A course of prednisolone did not result in any improvement and he died nine weeks after the onset of jaundice.
CONCLUSIONS: The cholestatic hepatitis induced by Augmentin is usually reversible but may be progressive, leading to death. The concurrent administration of ethinyloestradiol, a potentially cholestatic agent, may have altered the susceptibility and/or course of the reaction in this patient.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738330     DOI: 10.5694/j.1326-5377.1992.tb139752.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

1.  Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid.

Authors:  J P Richardet; A Mallat; E S Zafrani; M Blazquez; J C Bognel; B Campillo
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

2.  Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid.

Authors:  R J Andrade; M I Lucena; M C Fernández; J L Vega; R Camargo
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

Review 3.  Antibacterial-induced hepatotoxicity. Incidence, prevention and management.

Authors:  D K George; D H Crawford
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

4.  Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

Authors:  J O'Donohue; K A Oien; P Donaldson; J Underhill; M Clare; R N MacSween; P R Mills
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

Review 5.  Oral contraceptives. Are drug interactions of clinical significance?

Authors:  G M Shenfield
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 6.  Acute liver failure due to amoxicillin and amoxicillin/clavulanate.

Authors:  Robert J Fontana; A Obaid Shakil; Joel K Greenson; Ian Boyd; William M Lee
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.